Even mild and moderate side effects can contribute to patients with cancer discontinuing their treatment, according to an analysis recently published in the Journal of Clinical Oncology.
Browsing: Clinical Breakthroughs
Northwestern Medicine has launched the Human Longevity Laboratory, a longitudinal, cross-sectional study that will investigate the relationship between chronological age and biological age and validate interventions that may reverse or slow down the processes of aging.
Residents are more likely to flourish in their training programs and daily lives when peer-support is strong and leadership prioritizes residents’ wellbeing, according to results from a multi-institutional survey published in Annals of Internal Medicine.
Anti-inflammatory drugs alone are not sufficient to prevent pancreas inflammation following a common endoscopic procedure, according to a study recently published in The Lancet.
A lack of cancer progression could be used as a surrogate for overall survival in newly metastatic prostate cancer clinical trials, according to a new meta-analysis published in the Journal of Clinical Oncology.
An experimental drug designed to block blood-clotting proteins may slightly lower the risk of recurrent strokes, according to a dose-finding trial published in The Lancet Neurology.
The drug tovorafenib may halt the growth of or shrink some childhood brain tumors, according to a clinical trial published in Nature Medicine.
A multidisciplinary team of investigators has developed a first-of-its-kind interactive 3D spatial approach that reveals new therapeutic targets and provides a comprehensive three-dimensional view of glioblastoma tumors, detailed in a recent study published in Cell.
Nearly two-thirds of patients with diabetes either discontinued their second-line medication, switched to a different medication class or intensified their treatment, according to a recent study.
Northwestern Medicine investigators have identified a previously unknown regulator of tumor immune evasion, which may help improve the efficacy of current and future anti-tumor immunotherapies, according to recent findings published in the Journal of Clinical Investigation.